ICI (Immune Checkpoint Inhibitor Induced) Arthritis

Description

In this engaging episode of the podcast presented by HSS, Anne Bass, an attending physician at the Hospital for Special Surgery, hosts a discussion with two esteemed guests: Dr. Deanna Jannat-Khah, an Assistant Scientist at HSS and Assistant Professor of Epidemiology at Weill Cornell Medical College, and Dr. Michael Postow, a Melanoma Medical Oncologist at Memorial Sloan Kettering Cancer Center. The episode delves into the topic of immune checkpoint inhibitor-induced arthritis, a significant consideration for patients undergoing cancer treatment with immune therapy.



The conversation begins with an overview of the advancements in immunotherapy, focusing on immune checkpoint inhibitors that have revolutionized cancer treatment. Dr. Postow provides insight into the historical development of these therapies and the recognition of autoimmune side effects that can arise as a consequence. Both physicians discuss how cancer treatment strategies have evolved from traditional methods targeting rapidly dividing cells to harnessing the immune system to combat cancer.



As the episode progresses, the hosts and their guests discuss the prevalence and impact of immune checkpoint inhibitor-induced arthritis on patient quality of life. Dr. Jannat-Khah shares her research on inflammatory arthritis that develops as a result of these treatments, emphasizing that the condition can manifest in unique and complex ways. The panel reflects on the challenges of managing patients with pre-existing autoimmune conditions who require immunotherapy, with a focus on the importance of a multidisciplinary approach to patient care.



Listeners will appreciate the evidence-based discussion of treatment options, including the use of corticosteroids and biologic therapies, as well as the importance of real-world data in understanding patient outcomes. The episode wraps up with reflections on the future of immunotherapy, the ongoing quest to separate efficacy from toxicity, and the hopeful advancements in more tailored treatments for patients with cancer.

Specialties